Nkarta Unveils Early But Promising Data For CAR-NK Therapies In AML, NHL

 
• By Alaric DeArment

NKX101 in acute myeloid leukemia and NKX019 in non-Hodgkin’s lymphoma showed high complete response rates, but without the toxicity associated with CAR-Ts.

Acute myeloid leukemia a 3d-Render
Nkarta unveiled data for its CAR-NK therapies in AML and NHL • Source: Shutterstock

More from Immuno-oncology

More from Anticancer